Pharma supply chain companies form alliance to accelerate sustainability
Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target
Eight pharma and biotech supply chain companies have founded the Alliance to Zero, a non-profit membership organisation with the aim of facilitating the transition of the pharma sector to achieve net zero emissions in line with the Paris Climate Agreement.
The founders of the non-profit membership association represent key parts of the pharma supply, including component suppliers, machine suppliers and assembly/manufacturing service providers, as well as those involved in primary and secondary packaging to final device assembly and even collection after use.
In a statement, the Alliance to Zero said there is an urgent need to collaborate across the pharmaceutical supply chain.
"While there is much discussion in the pharma community today about sustainability and climate impact, substantial change among supply chain partners and manufacturers is not happening fast enough to reduce the emissions footprint," it said.
In addition, the Alliance to Zero said its founding companies recognise that proactive collaboration across traditional company boundaries is the way to develop solutions that will have broad acceptance and a positive impact on the pharmaceutical industry.
The Alliance to Zero intends to involve, connect and coordinate suppliers, pharmaceutical companies, manufacturers and service providers along the supply chain and engage with academia and non-profit organisations with similar aims.
Sebastian Gerner, president of the Alliance to Zero, called this formation the "first step" in a "challenging but urgent journey".
"Enabling the launch of net zero pharmaceutical products in regulated markets will require companies like ours to transform our operations, products, services, logistics, innovations and investments,” said Gerner.
Already, the alliance has started work on developing a roadmap detailing what a net zero emission concept for pharmaceutical manufacturing and supply chain would look like and the steps necessary to achieve it.
This foundational work also includes agreement on harmonized language and principles for the assessment and control of the total emission footprint for the final pharmaceutical products, as well as the company-specific responsibilities.
The founding members are Datwyler, Harro Hoflinger, HealthBeacon, Körber Pharma, SCHOTT, Schreiner MediPharm, Sharp, and Ypsomed Holding.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance